Literature DB >> 18555663

Nuclear Dbf2-related protein kinases (NDRs) in isolated cardiac myocytes and the myocardium: activation by cellular stresses and by phosphoprotein serine-/threonine-phosphatase inhibitors.

Stephen J Fuller1, Sampsa Pikkarainen, El Li Tham, Timothy E Cullingford, Jeffery D Molkentin, Hauke Cornils, Alexander Hergovich, Brian A Hemmings, Angela Clerk, Peter H Sugden.   

Abstract

The nuclear Dbf2-related protein kinases 1 and 2 (NDR1/2) are closely-related AGC family kinases that are strongly conserved through evolution. In mammals, they are activated inter alia by phosphorylation of an hydrophobic domain threonine-residue [NDR1(Thr-444)/NDR2(Thr-442)] by an extrinsic protein kinase followed by autophosphorylation of a catalytic domain serine-residue [NDR1(Ser-281)/NDR2(Ser-282)]. We examined NDR1/2 expression and regulation in primary cultures of neonatal rat cardiac myocytes and in perfused adult rat hearts. In myocytes, transcripts for NDR2, but not NDR1, were induced by the hypertrophic agonist, endothelin-1. NDR1(Thr-444) and NDR2(Thr-442) were rapidly phosphorylated (maximal in 15-30 min) in myocytes exposed to some phosphoprotein Ser-/Thr-phosphatase 1/2 inhibitors (calyculin A, okadaic acid) and, to a lesser extent, by hyperosmotic shock, low concentrations of H(2)O(2), or chelerythrine. In myocytes adenovirally-transduced to express FLAG-NDR2 (which exhibited a mainly-cytoplasmic localisation), the same agents increased FLAG-NDR2 activity as assessed by in vitro protein kinase assays, indicative of FLAG-NDR2(Ser-282/Thr-442) phosphorylation. Calyculin A-induced phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 were inhibited by staurosporine, but not by other protein kinase inhibitors tested. In ex vivo rat hearts, NDR1(Thr-444)/NDR2(Thr-442) were phosphorylated in response to ischaemia-reperfusion or calyculin A. From a pathological viewpoint, we conclude that activities of NDR1 and NDR2 are responsive to cytotoxic stresses in heart preparations and this may represent a previously-unidentified response to myocardial ischaemia in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555663     DOI: 10.1016/j.cellsig.2008.04.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  6 in total

1.  MICAL-1 is a negative regulator of MST-NDR kinase signaling and apoptosis.

Authors:  Yeping Zhou; Youri Adolfs; W W M Pim Pijnappel; Stephen J Fuller; Roel C Van der Schors; Ka Wan Li; Peter H Sugden; August B Smit; Alexander Hergovich; R Jeroen Pasterkamp
Journal:  Mol Cell Biol       Date:  2011-07-05       Impact factor: 4.272

2.  Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1/2) are formed endogenously in intact cardiac myocytes and are enzymically active.

Authors:  Peter H Sugden; Thomais Markou; Stephen J Fuller; El Li Tham; Jeffery D Molkentin; Hugh F Paterson; Angela Clerk
Journal:  Cell Signal       Date:  2010-10-30       Impact factor: 4.315

3.  A novel non-canonical mechanism of regulation of MST3 (mammalian Sterile20-related kinase 3).

Authors:  Stephen J Fuller; Liam J McGuffin; Andrew K Marshall; Alejandro Giraldo; Sampsa Pikkarainen; Angela Clerk; Peter H Sugden
Journal:  Biochem J       Date:  2012-03-15       Impact factor: 3.857

4.  The Neurospora crassa PP2A Regulatory Subunits RGB1 and B56 Are Required for Proper Growth and Development and Interact with the NDR Kinase COT1.

Authors:  Hila Shomin-Levi; Oded Yarden
Journal:  Front Microbiol       Date:  2017-09-05       Impact factor: 5.640

5.  MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins.

Authors:  Stephen J Fuller; Nick S Edmunds; Liam J McGuffin; Michelle A Hardyman; Joshua J Cull; Hajed O Alharbi; Daniel N Meijles; Peter H Sugden; Angela Clerk
Journal:  Biochem J       Date:  2021-06-11       Impact factor: 3.857

Review 6.  The Roles of NDR Protein Kinases in Hippo Signalling.

Authors:  Alexander Hergovich
Journal:  Genes (Basel)       Date:  2016-05-18       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.